Case Studies
Strategic Choice of Endpoints Led to Early Initiation of Trial Cohort Expansion and Capital Raise
Aug 18, 2026
Latest Resources
View All Articles
Case Studies
Aug 18, 2026
Strategic Choice of Endpoints Led to Early Initiation of Trial Cohort Expansion and Capital Raise
Our client a mid-sized Europe based biotechnology company was set to investigate the efficacy of their novel therapeutic in a rare disease.
Read the release notes
Case Studies
Phase IIA Study Brought to Successful Early Conclusion After Efficacy Results Announced
Aug 18, 2026
Case Studies
Supporting Business Decisions through Transparency of Execution
Aug 18, 2026
Case Studies
Reducing Length & Cost of Trials through Patient Stratification
Aug 18, 2026
Case Studies
Clinical Trial Outcomes with DYNAMIKA: A Case Study in Auto-Immune Disease Research
Aug 18, 2026
Case Studies
A Case Study in Innovative Imaging Analysis for Rare Disease Trials
Aug 18, 2026
Case Studies
Phase IIA Study Brought to Successful Early Conclusion After Efficacy Results Announced
Aug 18, 2026
Case Studies
Clinical Trial Outcomes with DYNAMIKA: A Case Study in Auto-Immune Disease Research
Aug 18, 2026
Case Studies
A Case Study in Innovative Imaging Analysis for Rare Disease Trials
Aug 18, 2026
Case Studies
Innovative Approach Revitalizes Drug Development in Challenging Therapeutic Area
Aug 18, 2026
Case Studies
Optimizing Clinical Trial Design: A Case Study in Strategic Biomarker Selection
Aug 18, 2026
Case Studies
How Image Analysis Group (IAG) Supported SynAct Pharma’s Resomelagon (AP1189) Phase 2b EXPAND Program
Jul 18, 2026